ReviewBlood2013
Challenges and promises for the development of donor-independent platelet transfusions.
Review in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- First evidence of the circulation of induced pluripotent stem cell-derived platelets in humans.Stem cells translational medicine · 2026Article
- Lyophilized Synthetic Platelets: In Vitro Characterization and In Vivo Evaluation in Mouse Thrombocytopenia Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- The Kifc3 Motor Protein Controls Centrosomal Factor Cep192 in Ontogenic Coordination of Megakaryocyte Development.bioRxiv : the preprint server for biology · 2026Article
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease.Journal of nanobiotechnology · 2025Review
- Observational
- A circle of life: platelet and megakaryocyte cytoskeleton dynamics in health and disease.Open biology · 2024Review
- Platelet-rich plasma: a comparative and economical therapy for wound healing and tissue regeneration.Cell and tissue banking · 2023Review
- Applications of injectable hemostatic materials in wound healing: principles, strategies, performance requirements, and future perspectives.Theranostics · 2023Review
- Article
- Platelet-Inspired Intravenous Nanomedicine for Injury-Targeted Direct Delivery of Thrombin to Augment Hemostasis in Coagulopathies.ACS nano · 2022Article
- Relieving DYRK1A repression of MKL1 confers an adult-like phenotype to human infantile megakaryocytes.The Journal of clinical investigation · 2022Article
- Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation.Journal of thrombosis and haemostasis : JTH · 2022Review
- Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding.Science translational medicine · 2022Article
- Bioinspired artificial platelets: past, present and future.Platelets · 2022Review
- High-Throughput Production of Platelet-Like Particles.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Developments in the production of platelets from stem cells (Review).Molecular medicine reports · 2021Review
- Specific Blood Cells Derived from Pluripotent Stem Cells: An Emerging Field with Great Potential in Clinical Cell Therapy.Stem cells international · 2021Review
- Incidence and severity of adverse events among platelet donors: A three-year retrospective study.Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Platelet transfusions are often a life-saving intervention, and the use of platelet transfusions has been increasing. Donor-derived platelet availability can be challenging. Compounding this concern are additional limitations of donor-derived platelets, including variability in product unit quality and quantity, limited shelf life and the risks of product bacterial contamination, other transfusion-transmitted infections, and immunologic reactions. Because of these issues, there has been an effort to develop strategies to generate platelets from exogenously generated precursor cells. If successful, such platelets have the potential to be a safer, more consistent platelet product, while reducing the necessity for human donations. Moreover, ex vivo-generated autologous platelets or precursors may be beneficial for patients who are refractory to allogeneic platelets. For patients with inherited platelet disorders, ex vivo-generated platelets offer the promise of a treatment via the generation of autologous gene-corrected platelets. Theoretically, ex vivo-generated platelets also offer targeted delivery of ectopic proteins to sites of vascular injury. This review summarizes the current, state-of-the-art methodologies in delivering a clinically relevant ex vivo-derived platelet product, and it discusses significant challenges that must be overcome for this approach to become a clinical reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.